
Lundbeck appoints new global pricing and market access VP
pharmafile | January 11, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â Eggert, Jaszewski, LundbeckÂ
Barbara Jaszewski, has been appointed vice president of global pricing and market access at Lundbeck.
She will be in charge of developing and strengthening a business area of growing strategic significance to Lundbeck as the firm prepares to launch a range of new drugs.
Jaszewski will lead the ongoing work of further building the company’s global market access from its Danish headquarters, and help Lundbeck implement the strategy of integrating and consolidating this business area more widely across the organisation.
Jaszewski will report to Andreas Eggert, senior vice president of global product strategy and portfolio development, who said: “Barbara Jaszewski will play an important role in leading our efforts to further strengthen Lundbeck’s commercial business processes, and will help our organisation support future product launches in the best way possible.”
Jaszewski has more than 20 years of experience in market access in the international pharma industry. She comes from a position as director of global market access in the Berlin office of German company Bayer Healthcare, where she was responsible for setting up Bayer’s regional market access activities in Europe, Canada, Russia, Turkey, the Middle East and Africa. Prior to that, she held positions in the Canadian subsidiaries of Bayer and GSK.
Related Content

Otsuka and Lundbeck gain FDA approval for supplemental New Drug Application for dementia drug
Japan-based healthcare company Otsuka Pharmaceutical and Danish pharma company Lundbeck have announced that the US …

Lundbeck to restructure R&D, shedding up to 160 jobs
Danish neuroscience specialist Lundbeck has announced it will be implementing a restructure of its Research …

Lundbeck’s Vyepti secures US approval for migraine prevention
Lundbeck’s Vyepti (eptinezumab-jjmr) has secured approval from the FDA, it has emerged, for the prevention …






